Cargando…
Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
Thyroid cancer is the most common (~90%) type of endocrine-system tumor, accounting for 70% of the deaths from endocrine cancers. In the last years, the high-throughput genomics has been able to identify pathways/molecular targets involved in survival and tumor progression. Targeted therapy and immu...
Autores principales: | Ragusa, Francesca, Ferrari, Silvia Martina, Elia, Giusy, Paparo, Sabrina Rosaria, Balestri, Eugenia, Botrini, Chiara, Patrizio, Armando, Mazzi, Valeria, Guglielmi, Giovanni, Foddis, Rudy, Spinelli, Claudio, Ulisse, Salvatore, Antonelli, Alessandro, Fallahi, Poupak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144613/ https://www.ncbi.nlm.nih.gov/pubmed/35628540 http://dx.doi.org/10.3390/ijms23105731 |
Ejemplares similares
-
Molecular features of aggressive thyroid cancer
por: Elia, Giusy, et al.
Publicado: (2022) -
ODP598 Liquid levothyroxine (L-T4) maintains more stable TSH levels in hypothyroid patients, than tablet L-T4
por: Antonelli, Alessandro, et al.
Publicado: (2022) -
PSAT366 Liquid L-thyroxine (L-T4) Formulation Normalizes TSH in Hypothyroid Patients Treated with Tablets L-T4
por: Antonelli, Alessandro, et al.
Publicado: (2022) -
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series
por: Fallahi, Poupak, et al.
Publicado: (2022) -
Myoinositol in Autoimmune Thyroiditis
por: Paparo, Sabrina Rosaria, et al.
Publicado: (2022)